HEALWELL AI CEO Dr. Alex Dobranowski interview at Cantech 24

Let’s get away from the country being a “break-fix model” when it comes to healthcare.

That’s where HEALWELL AI (HEALWELL AI Stock Quote, Chart, News, Analysts, Financials TSX:AIDX) CEO Dr. Alex Dobranowski thinks his upstart tech company can offer the healthcare system, offering instead a model based on prevention.

Dobranowski sat down with Amber Mac for an interview at Cantech 24 in Toronto October 9. The CEO explained what kind of the progress the company made in 2024 and how it is having an immediate affect on patient outcomes in Canada.

“I’m really proud of what we have been able to do over the past twelve months,” Dobranowski said. “Our technology now is in production at scale, and what I mean by that is we have nearly a thousand physicians who use the technology. We have been able to screen millions of patient records and identify patients at high risk of conditions. There are thousands of patients we have helped identify, and that’s really moving the needle forward on preventative care.”

Equity analysts are liking what they see from HEALWELL AI. In a research update to clients October 7, Haywood analyst Gianluca Tucci initiated coverage of the stock with a “Buy” rating and price target of $2.50, implying a return of 75% at the time of publication.

The analyst says growth-through-acquisition is a key pillar of the company’s business plan.

“In less than one year, AIDX has acquired four companies (Pentavere, Intrahealth, Verosource, Bio Pharma) across AI data science, SaaS/Technology, and trial specialty services, while raising over $50M in gross proceeds through debt and equity,” the analyst noted. “Its proforma revenue run rate is ~$75M and the Company envisions a scenario where it exits 2024 approaching a $100M revenue run rate, implying additional acquisition(s) in the near-term pipeline. AIDX is also targeting a turn to Adj. EBITDA profitability in 2025, with additional EBITDA generating acquisitions.”

For the full interview see below.